Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.

about

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.

Item

http://www.wikidata.org/entity/Q48157814

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@en

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@nl

type

Item

label

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@en

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@nl

prefLabel

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@en

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@nl

P1476

Prevention of Invasive Aspergi ...... ith Haematologic Malignancies.

@en

P2093

David Combarel

http://www.w3.org/2001/XMLSchema#string

Elisabeth Leclerc

http://www.w3.org/2001/XMLSchema#string

Madalina Uzunov

http://www.w3.org/2001/XMLSchema#string

Noël Zahr

http://www.w3.org/2001/XMLSchema#string

Véronique Leblond

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic Drug Monitoring of Posaconazole: an Update

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P2888

s41598-018-20136-3

P304

1681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-20136-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Funck-Brentano

P577

2018-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29374234

http://www.w3.org/2001/XMLSchema#string

P932

5785994

http://www.w3.org/2001/XMLSchema#string